Sponsor pipeline

Novartis Pharmaceuticals clinical trial pipeline

Get alerts when Novartis Pharmaceuticals's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

67 trials changed in the last 30 days: 3 stopped, 21 with notable changes, 43 with minor changes only.

  1. Stopped

    Withdrawn before enrolling

    Sponsor's reason: Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint

    Also in this update: Primary and study completion pushed from Dec 7, 2028 to Jan 22, 2029

    Novartis PharmaceuticalsPhase 3 NCT07625306 Registry history

    Updated

  3. Stopped

    Trial status changed: Recruiting → Withdrawn

    Sponsor's reason: The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.

    Also in this update: Trial sites reduced: 25 → 0 locations

    Novartis PharmaceuticalsPhase 2 NCT07039422 Registry history

    Updated

  4. Notable

    Primary and study completion pushed from Nov 30, 2026 to May 31, 2027

    Novartis PharmaceuticalsNot specified NCT07677267 Registry history

    Updated

  14. Notable

    Recruitment opened

    Also in this update: Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026; Primary and study completion moved earlier from Jul 17, 2028 to Jun 2, 2028; and 1 more change in the last 30 days

    Novartis PharmaceuticalsPhase 3 NCT07816328 Registry history

    Updated

  16. Notable

    Recruitment opened

    Also in this update: Primary and study completion pushed from Sep 16, 2027 to Oct 19, 2027; Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026; and 3 more changes in the last 30 days

    Novartis PharmaceuticalsPhase 2 NCT07830719 Registry history

    Updated

Show 43 trials with minor changes only
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-09 NCT07868328 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary… Phase 2 Not Yet Recruiting
2026-10-02 NCT07855276 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to… Phase 1 Not Yet Recruiting
2026-09-30 NCT07850752 A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With… Phase 3 Not Yet Recruiting
2026-09-28 NCT07843758 An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant… Completed
2026-09-28 NCT07844070 A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During… Active, Not Recruiting
2026-09-24 NCT07839858 A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment… Completed
2026-09-21 NCT07830719 Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… Phase 2 Recruiting

Active trials by phase

Phase 1
43
Phase 1/2
26
Phase 2
69
Phase 2/3
2
Phase 3
90
Phase 4
25
Not charted: 113 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 368

NCT IDTitleConditionStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Melanoma Recruiting 2026-10-14
NCT04638647 Secukinumab Open Label Roll-over Extension Protocol Autoimmunity, Inflammation Recruiting 2026-10-13
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… Spinal Muscular Atrophy Recruiting 2026-09-18
NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to… Hidradenitis Suppurativa (HS) Recruiting 2026-09-09
NCT04877522 Asciminib Roll-over Study Chronic Myelogenous Leukemia Recruiting 2026-07-06
NCT04480853 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… Multiple Sclerosis Recruiting 2026-06-26
NCT04657822 Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… Sickle Cell Disease Recruiting 2026-06-08
NCT06824103 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… Graft vs. Host Disease Recruiting 2026-06-08
NCT05803941 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate… Prostate Cancer Recruiting 2026-06-04
NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting 2026-05-15
NCT07034690 Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in… Atherosclerotic Cardiovascular Disease Recruiting 2026-05-04
NCT06501443 LATAM LOWERS LDL-C Hypercholesterolaemia Recruiting 2025-12-30
NCT05622708 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With… Non-radiographic Axial Spondyloarthritis Active, Not Recruiting 2026-10-14
NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib Metastatic Breast Cancer Active, Not Recruiting 2026-10-09
NCT02584933 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… ALK Positive Malignancies Active, Not Recruiting 2026-09-17
NCT05252585 A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… Renal Angiomyolipoma Active, Not Recruiting 2026-09-17
NCT06462469 Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV… Steroid-refractory Acute Graft Versus Host Disease Active, Not Recruiting 2026-09-17
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study Diffuse Astrocytoma Active, Not Recruiting 2026-08-27
NCT02386800 CINC424A2X01B Rollover Protocol Primary Myelofibrosis Active, Not Recruiting 2026-08-20
NCT06444113 Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… Multiple Sclerosis Active, Not Recruiting 2026-08-12
NCT06372925 Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute… Plaque, Atherosclerotic Active, Not Recruiting 2026-07-28
NCT07713602 Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in… Malaria Not Yet Recruiting 2026-07-20
NCT07684469 Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care… Acute Coronary Syndrome Not Yet Recruiting 2026-07-06
NCT05090371 A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… Relapsing-Remitting Multiple Sclerosis Active, Not Recruiting 2026-05-29
NCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Coronary Heart Disease Active, Not Recruiting 2026-05-29
See all 368 active Novartis Pharmaceuticals trials with filters →

Disease areas by active trials, top 10 of 63

Breast Cancer (33) · Prostate Cancer (32) · Leukemia (27) · Multiple Sclerosis (27) · Lung Cancer (23) · Heart Disease (22) · Non-Small Cell Lung Cancer (NSCLC) (18) · Hidradenitis Suppurativa (16) · Chronic Myeloid Leukemia (CML) (15) · Colorectal Cancer (9)

Get alerts when Novartis Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free